Aishi and Mercadon's potential first-line combination therapy recognized by FDA breakthrough therapy
-
Last Update: 2020-06-02
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The designation of "breakthrough therapy" is an FDA policy designed to accelerate the development and review of drugs for the treatment of serious or life-threatening diseasesTo qualify for this designation, preliminary clinical evidence must prove that the therapy may provide a substantial improvement over the currently available therapy at at least one clinically important endpointthis "breakthrough therapy" designation is based on the latest interim results of the Phase 1b trial KEYNOTE-524/116 studyThe study presented the results of the mid-term analysis of the trial at the 2019 annual meeting of the American Association for Cancer Research (AACR)the combination of the rapa is still in trial, its efficacy and safety have not yet been determined, and has not yet been approved for the treatment of any type of cancerNote: The original text has a limitationoriginal title: Aishi and Mersadon's potential first-line combination therapy is fda-recognized
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
